Core Viewpoint - 康哲药业's subsidiary 德镁医药 is seeking independent listing on the Hong Kong Stock Exchange and has received clinical trial approval for povorcitinib from the NMPA for treating non-segmental vitiligo and moderate to severe hidradenitis suppurativa [1] Group 1 - 德镁医药 has been granted a drug clinical trial approval notice by the NMPA on August 28, 2025, for povorcitinib [1] - Povorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions [1] - The drug is currently undergoing phase 3 clinical trials for non-segmental vitiligo, hidradenitis suppurativa, and nodular prurigo in several overseas countries, along with phase 2 trials for asthma and chronic spontaneous urticaria [1]
康哲药业:创新药口服小分子JAK1抑制剂Povorcitinib获得白癜风、化脓性汗腺炎适应症药物临床试验批准通知书